Citations

Clear

7 citation(s) found for "Mehta, Amit".

Inflammasome-resistant IPSC-derived myeloid-derived suppressor cells ameliorate xenogeneic graft-versus-host disease
Ma, Lie , Koehn, Brent H. , Zaiken, Michael , Hippen, Keli L. , Smith, Kyle D. , Allred, Jeremy , Williams, Robin , Yao, Ke , Fink, Jordan , Saha, Asim , Payne, Nathaniel, Widelak, Renata, Tolar, Jakub , Xia, Lily , Witty, Alec, Mehta, Amit, Denholtz, Matthew, Hani, Sophia , Kean, Leslie S. , Valamehr, Bahram , Koehn, Brent , Tolar, Jakub , Eide, Cindy , Kenderian, Saad S. , Molldrem, Jeffrey J , Valamehr, Bahram , Blazar, Bruce R , Yao, Ke , Koop, Benjamin, Payne, Nathaniel, Panoskaltsis‐Mortari, Angela , Riddle, Megan J. , Hefazi, Mehrdad , Miller, Jeffrey S. , Molldrem, Jeffrey J. , Blazar, Bruce R.

Mayo Clinic

Blood | July 23, 2025 | Volume: 146 | Issue: 17 | Pages: 2047-2062

10.1182/blood.2025028562 | PMID 40700578 Get It

Abstract Front-line pharmaceutical interventions for treating acute graft-versus-host disease (GVHD) are not uniformly effective and have toxic side effects. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with potent in vitro and in vivo immunosuppressive functions. Clinical translation of in vitro–generated MDSCs has been limited because of requirements for multiple, high infusion doses, the relatively low yield from peripheral blood–sourced MDSCs (PB-MDSCs), and inconsistent product quality. To circumvent these obstacles, we developed a methodology to generate MDSCs using human induced pluripotent stem cell (iPSC)–derived CD34+ cells. Compared with PB-MDSCs, iPSC-derived MDSCs (iMDSCs) shared similar morphology, phenotype, and suppressive function. We found that the CD14+ iMDSC subset possessed the highest suppressor function. In previous studies, we reported that MDSCs transferred into mice with GVHD lost suppressor function because of inflammasome activation and immature myeloid cell maturation. In striking contrast to human PB-MDSCs, we show herein that iMDSCs retained 95% of suppressor function in vitro despite exposure to lipopolysaccharide (LPS) plus adenosine triphosphate (ATP), which are stimuli that activate the inflammasome via danger-associated molecular patterns released during early posttransplant conditioning and GVHD-induced injury. In an in vivo xenogenic GVHD model with PB mononuclear cells, iMDSCs significantly increased recipient survival without loss of antileukemia effects. iMDSC RNA sequencing and gene knockdown studies revealed that the maintenance of the purine metabolizing enzyme, phosphoglycerate dehydrogenase, during LPS plus ATP treatment, was linked to iMDSC inflammasome resistance. Taken together, these findings provide a platform for translating in vitro–generated, off-the-shelf iMDSCs into the clinic for suppressing a spectrum of adverse immune responses, including GVHD.
Peroral endoscopic myotomy as a treatment for Killian–Jamieson diverticulum (KJ-POEM)
Assefa, Redeat Libanos, Bejjani, Michael , Mehta, Amit , Shrigiriwar, Apurva , Shimamura, Yuto , Inoue, Haruhiro , Mandarino, Francesco Vito , Bowers, Steven P. , Arevalo, Martha, Andrisani, Gianluca , Sampath, Kartik, Khashab, Mouen A., Shimamura, Yuto , Mandarino, Francesco Vito , Lajin, Michael , Assefa, Redeat, Fayyaz, Farimah , Azzolini, Francesco , Li, Zhen , Robles‐Medranda, Carlos , Arevalo-Mora, Martha , Dhir, Vinay K. , Tanțău, Alina Ioana , Khashab, Mouen A.

Mayo Clinic

Endoscopy International Open | September 18, 2024 | Volume: 12 | Issue: 10 | Pages: E1214-E1219

10.1055/a-2399-7464 | PMID 39474487 Get It

Abstract Background and study aims Killian-Jamieson diverticulum (KJD) is a rare type of esophageal diverticulum that occurs in a specific area called the Killian-Jamieson space. Although surgery has been the conventional treatment for symptomatic KJD, minimally invasive endoscopic techniques, particularly Killian-Jamieson per-oral endoscopic myotomy (KJ-POEM), have emerged as an alternative. The aim of the study was to evaluate the effectiveness and safety of KJ-POEM in treating KJD. Patients and methods This was an international, multicenter, retrospective study that included patients who underwent KJ-POEM for symptomatic KJD from October 16, 2018 to April 12,2023. The primary outcome was clinical success, defined as complete or near-complete resolution of symptoms (i.e., post-procedure Kothari-Haber Score ≤ 2). Secondary outcomes were technical success (defined as successful completion of all procedural steps), rate and severity of adverse events (AEs), total procedure duration, and symptom recurrence during follow-up. Results A total of 13 patients (mean age 65.23 years, 6 female) with KJD and a mean pre-procedure Kothari-Haber Score of 6 (standard deviation [SD] 2.16) underwent KJ-POEM across 10 participating centers. Clinical success and technical success were achieved in all cases (100%) with a mean post-procedure Kothari-Haber Score of 0.91 (SD 0.99). There were no AEs and no cases of injury to the recurrent laryngeal nerve. Mean length of hospital stay was 1.09 days (SD 0.74). Mean follow-up time was 9.41 months (SD 10.07) post-procedure. There was no post-procedure symptom recurrence any patient. Conclusions KJ-POEM is a safe and effective alternative treatment for symptomatic KJD with excellent short/mid-term outcomes.
A novel through-the-scope helix tack-and-suture device for mucosal defect closure following colorectal endoscopic submucosal dissection: a multicenter study
Farha, Jad , Ramberan, Hemchand, Aihara, Hiroyuki , Zhang, Linda Y. , Mehta, Amit , Hage, Camille , Schlachterman, Alexander , Kumar, Anand , Shinn, Brianna , Canakis, Andrew , Kim, Raymond E., Buscaglia, Jonathan M. , Samarasena, Jason , Chang, Kenneth J. , Friedland, Shai , Qumseya, Bashar , Jawaid, Salmaan , Othman, Mohamed O. , Hasan, Muhammad K. , Khashab, Mouen A., Ngamruengphong, Saowanee , group, ESD-Closure working, Storm, Andrew C , Othman, Mohamed O , Canakis, Andrew , D'Souza, Lionel S. , Storm, Andrew C. , Draganov, Peter V. , Yang, Dennis J. , Khashab, Mouen A. , group, ESD-Closure working

Mayo Clinic

Endoscopy | November 3, 2022 | Volume: 55 | Issue: 06 | Pages: 571-577

10.1055/a-1970-5528 | PMID 36323330 Get It

Background Complete closure of large mucosal defects following colorectal endoscopic submucosal dissection (ESD) with through-the-scope (TTS) clips is oftentimes not possible. We aimed to report our early experience of using a novel TTS suturing system for the closure of large mucosal defects after colorectal ESD. Methods We performed a retrospective multicenter cohort study of consecutive patients who underwent attempted prophylactic defect closure using the TTS suturing system after colorectal ESD. The primary outcome was technical success in achieving complete defect closure, defined as a < 5 mm residual mucosal defect in the closure line using TTS suturing, with or without adjuvant TTS clips. Results 82 patients with a median defect size of 30 (interquartile range 25–40) mm were included. Technical success was achieved in 92.7 % (n = 76): TTS suturing only in 44 patients (53.7 %) and a combination of TTS suturing to approximate the widest segment followed by complete closure with TTS clips in 32 (39.0 %). Incomplete/partial closure, failure of appropriate TTS suture deployment, and the need for over-the-scope salvage closure methods were observed in 7.3 % (n = 6). One intraprocedural bleed, one delayed bleed, and three intraprocedural perforations were observed. There were no adverse events related to placement of the TTS suture. Conclusion The TTS suture system is an effective and safe tool for the closure of large mucosal defects after colorectal ESD and is an alternative when complete closure with TTS clips alone is not possible.
Impact of Adjunctive Pharmacotherapy With Intragastric Balloons for the Treatment of Obesity
Mehta, Amit , Shah, Shawn L. , Dawod, Enad , Hajifathalian, Kaveh , Kumar, Rekha B. , Igel, Leon I. , Saunders, Katherine H. , Kumbhari, Vivek , Farha, Jad , Badurdeen, Dilhana, Itani, Mohamad I. , Moore, Rachel , Starpoli, Anthony A., Carr‐Locke, David L. , Shukla, Alpana P. , Aronne, Louis J. , Sharaiha, Reem Z.

Mayo Clinic

The American Surgeon™ | August 12, 2021 | Volume: 89 | Issue: 4 | Pages: 707-713

10.1177/00031348211038579 | PMID 34384255 Get It

Background We conducted this study to compare the weight loss outcome of intragastric balloons (IGBs) in conjunction with pharmacotherapy vs IGB and intensive lifestyle changes alone. Methods This was a multicenter, non-randomized, retrospective study involving 4 academic hospitals. Patients underwent IGB placement with or without concomitant anti-obesity pharmacotherapy. The primary outcome was percent total weight loss (TBWL) after IGB placement at 6 and 12 months. Results This study included 102 patients, with 23 patients (mean age 46.6 years, 82.6% female) treated with IGB/pharmacotherapy and 79 patients (mean age 46.0 years, 88.6% female) treated with IGB/lifestyle modifications. Patients had a 100% follow-up rate at 6 and 12 months. At 6 months following IGB placement, both groups achieved a similar %TBWL. At 12 months, %TBWL was greater in the IGB/pharmacotherapy group (12.6% ± 1.2 vs 9.7% ± 0.7, P = .04). 65.2% of patients achieved ≥10% TBWL at 12 months in the IGB/pharmacotherapy group, compared to 38.0% in the IGB/lifestyle group ( P < .05). The proportion of patients that achieved ≥15% weight loss at 12 months was also significantly different between the IGB/pharmacotherapy and IGB/lifestyle groups (30.4% vs 20.3%, P < .05). Discussion IGB with concomitant use of pharmacotherapy did not improve weight loss while the IGB was in place compared to IGB and lifestyle changes. However, patients receiving IGB with pharmacotherapy did have greater weight loss and diminished weight regain after balloon removal compared to those receiving just IGB and lifestyle changes.
Healthcare Worker With Large Vessel Acute Ischemic Stroke Likely Related to Mild SARS-CoV-2 Infection
Castillo, Carlos , Lamotte, Guillaume , Mehta, Amit , Sonti, Rajiv , Maria, Gianluca Di, Ruiz, Daniel Carnevali , Kumar, Princy , Stemer, Andrew B., Denny, Mary Carter , Castillo-Pinto, Carlos , Denny, M Carter , Mehta, Amit , Lamotte, Guillaume

Mayo Clinic

The Neurohospitalist | November 10, 2020 | Volume: 12 | Issue: 1 | Pages: 48-56

10.1177/1941874420966845 | PMID 34950386 Get It

We report the case of a healthcare worker who presented with a large vessel acute ischemic stroke in setting of a mild SARS-CoV-2 infection and provide a review of the emerging literature on COVID-related stroke. A 43-year-old female presented with right-sided hemiparesis, aphasia and dysarthria. She had a nonproductive of cough for 1 week without fever, fatigue or dyspnea. A CT Head, CT angiography and CT perfusion imaging revealed a M1 segment occlusion of the left middle cerebral artery requiring transfer from a primary to a comprehensive stroke center. A nasopharyngeal swab confirmed SARS-CoV-2 infection prior to arrival at the accepting center. During the thrombectomy a 3 cm thrombus was removed. Thrombus was also evident in the 8 French short sheath during closure device placement so a hypercoagulable state was suspected. Stroke work-up revealed a glycosylated hemoglobin of 8.7%, elevation of inflammatory markers and an indeterminate level of lupus anticoagulant IgM. On discharge home, she had near complete neurological recovery. This case highlights suspected mechanisms of hypercoagulability in SARS-CoV-2 infection and the importance of optimizing stroke care systems during the COVID-19 pandemic.
Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer
Zhang, Yaqin , Mehta, Amit, Boufraqech, Myriem , Tian, Ze , Yu, Zhiya , Boxer, Matthew B., Kiefer, Jeffrey , Copland, John A. , Smallridge, Robert C., Li, Zhuyin, Kebebew, Electron , Zhang, Lisa M. , Davis, Sean , Wang, Jing , Shen, Min

Mayo Clinic

Oncotarget | September 15, 2015 | Volume: 6 | Issue: 11 | Pages: 9073-9085

10.18632/oncotarget.3268 | PMID 25940539 Get It

miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
Boufraqech, Myriem , Nilubol, Naris , Gara, Sudheer Kumar, Sadowski, Samira M. , Mehta, Amit, Davis, Sean , Dreiling, Jennifer L., Copland, John A. , Smallridge, Robert C., Quezado, Martha , Kebebew, Electron , Zhang, Lisa M. , He, Mei

Mayo Clinic

Cancer Research | December 9, 2014 | Volume: 75 | Issue: 2 | Pages: 367-377

10.1158/0008-5472.can-14-2304 | PMID 25488748 Get It

Abstract Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies, but its genetic drivers remain little understood. In this study, we report losses in expression of the miRNA miR30a, which is downregulated in ATC compared with differentiated thyroid cancer and normal tissue. miR30a downregulation was associated with advanced differentiated thyroid cancer and higher mortality. Mechanistically, we found miR30a decreased cellular invasion and migration, epithelial–mesenchymal transition marker levels, lysyl oxidase (LOX) expression, and metastatic capacity. LOX was identified as a direct target of miR30a that was overexpressed in ATC and associated with advanced differentiated thyroid cancer and higher mortality rate. Consistent with its role in other cancers, we found that LOX inhibited cell proliferation, cellular invasion, and migration and metastasis in vitro and in vivo. Together, our findings establish a critical functional role for miR30a downregulation in mediating LOX upregulation and thyroid cancer progression, with implications for LOX targeting as a rational therapeutic strategy in ATC. Cancer Res; 75(2); 367–77. ©2014 AACR.